Idelalisib and rituximab produce responses in 97% with CLL The Oncology Report CHICAGO – When paired with rituximab, the experimental agent idelalisib was associated with durable progression-free survival rates in older patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma, Dr. Susan M. O'Brien ... |
